Anti-fibrotic Effects of CXCR4-Targeting i-body AD-114 in Preclinical Models of Pulmonary Fibrosis.

about

Anti-fibrotic Effects of CXCR4-Targeting i-body AD-114 in Preclinical Models of Pulmonary Fibrosis.

Item

http://www.wikidata.org/entity/Q49912722

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Anti-fibrotic Effects of CXCR4 ...... Models of Pulmonary Fibrosis.

@en

Anti-fibrotic Effects of CXCR4 ...... Models of Pulmonary Fibrosis.

@nl

type

Item

label

Anti-fibrotic Effects of CXCR4 ...... Models of Pulmonary Fibrosis.

@en

Anti-fibrotic Effects of CXCR4 ...... Models of Pulmonary Fibrosis.

@nl

prefLabel

Anti-fibrotic Effects of CXCR4 ...... Models of Pulmonary Fibrosis.

@en

Anti-fibrotic Effects of CXCR4 ...... Models of Pulmonary Fibrosis.

@nl

P1476

Anti-fibrotic Effects of CXCR4 ...... l Models of Pulmonary Fibrosis

@en

P2093

A Skerra

http://www.w3.org/2001/XMLSchema#string

C G Hosking

http://www.w3.org/2001/XMLSchema#string

J Jaffar

http://www.w3.org/2001/XMLSchema#string

M Foley

http://www.w3.org/2001/XMLSchema#string

U Binder

http://www.w3.org/2001/XMLSchema#string

W G Darby

http://www.w3.org/2001/XMLSchema#string

P2860

Beta-arrestin- but not G protein-mediated signaling by the "decoy" receptor CXCR7

Cancer invasion and the microenvironment: plasticity and reciprocity

AMD3100 is a CXCR7 ligand with allosteric agonist properties

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management

Inhibition of the CXCL12/CXCR4-axis as preventive therapy for radiation-induced pulmonary fibrosis

i-bodies, Human Single Domain Antibodies That Antagonize Chemokine Receptor CXCR4.

Fibrocyte CXCR4 regulation as a therapeutic target in pulmonary fibrosis

P304

3212

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-018-20811-5

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-02-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29453386

http://www.w3.org/2001/XMLSchema#string

P921

pulmonary fibrosis

P932

5816662

http://www.w3.org/2001/XMLSchema#string